ALVEOLAR SOFT PART SARCOMA

This study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This early-stage trial tests whether giving a targeted drug (palbociclib) before immunotherapy (pembrolizumab) is safe and can help shrink tumors in people with certain soft tissue sarcomas. About 8 participants will receive the combination. The main goal is to check for side eff…

This study tests whether combining the immunotherapy drug pembrolizumab with chemotherapy drugs (melphalan and dactinomycin) delivered directly to the affected limb via isolated limb infusion can safely delay cancer growth. It enrolls 30 patients aged 12 and older with advanced s…

This phase II trial is testing whether a combination of two drugs—benmelstobart (an immunotherapy) and anlotinib (a targeted therapy)—can shrink tumors in people with advanced or inoperable alveolar soft part sarcoma, a rare cancer. The study will enroll 33 participants aged 14 a…

This study tests an experimental oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow cancer growth for at least 3 months. The drug targ…

This phase 3 trial tests the drug AL3818 (anlotinib) in people with advanced alveolar soft part sarcoma, leiomyosarcoma, or synovial sarcoma. Currently, only patients with alveolar soft part sarcoma are being enrolled. Participants receive AL3818 pills or a standard chemotherapy …

This study tests a new drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery or has spread. Participants receive the drug every 3 weeks. The main goal is to see if the cancer stays stable for at least 12 weeks. Researchers wil…

This study is collecting tumor and blood samples from 400 people with rare soft tissue sarcomas to learn how their immune system reacts to the cancer. Researchers will also track patients' health over time to see how the disease progresses. The goal is to find clues that could le…